Heron Therapeutics (HRTX) Receivables (2010 - 2026)

Heron Therapeutics (HRTX) has reported Receivables for 12 consecutive years, with $89.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 12.06% year-over-year to $89.6 million; the trailing twelve-month figure through Jun 2026 stood at $89.6 million (up 12.06% YoY), and the FY2025 full-year result was $89.9 million, up 13.63% from the prior year.
• Receivables climbed to $89.6 million in Q2 2026 per HRTX's latest filing, from $83.7 million in the prior quarter.
• Across five years, Receivables topped out at $89.9 million in Q4 2025 and bottomed at $40.3 million in Q2 2022.
• Historically, Receivables has averaged $67.9 million across 5 years, with a median of $70.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables slipped 5.43% in 2022, then surged 90.29% in 2023.
• Over 5 years, Receivables stood at $58.2 million in 2022, then gained by 3.78% to $60.4 million in 2023, then surged by 30.93% to $79.1 million in 2024, then climbed by 13.63% to $89.9 million in 2025, then declined by 0.4% to $89.6 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $89.6 million, $83.7 million, and $89.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.